

### **New drug for acute migraine**

A U.S. drugmaker has released positive data from its Phase III pivotal trial of Rimegepant for the treatment of migraines. Rimegepant is an oral calcitonin gene-related peptide (CGRP) antagonist. CGRP is released during an attack, resulting in pain. Rimegepant eases the pain and other symptoms by blocking the CGRP pathway.